Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis Patients
- 31 May 2011
- journal article
- research article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 57 (5), 724-732
- https://doi.org/10.1053/j.ajkd.2010.12.016
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences Models of Infectious Disease Agent Study (5U54GM088491-02)
- Vaccine Modeling Initiative
- Bill and Melinda Gates Foundation
- National Library of Medicine (5R01LM009132-03)
- Centers for Disease Control and Prevention (5P01HK000086-02)
This publication has 59 references indexed in Scilit:
- Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 monthsVaccine, 2010
- Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 YearsThe Pediatric Infectious Disease Journal, 2010
- Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in AdultsThe Journal of Infectious Diseases, 2010
- Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre studyBMJ, 2010
- Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstaclesVaccine, 2010
- Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trialVaccine, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responsesThe Lancet Infectious Diseases, 2009
- A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) populationVaccine, 2009
- Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjectsImmunity & Ageing, 2008